Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: A

Drug products: NovoNorm®, Repaglinid Actavis, Repaglinid Arrow, Repaglinid Sandoz, Repaglinid STADA, Repaglinide Accord, Repaglinide Krka, Repaglinide Teva

ATC code: A10BX02

Substances: repaglinide


No clinically relevant sex differences have been described. A retrospective cohort study has shown a possible higher risk of hospitalized heart failure for women.

Additional information

Studies indicate that men in the early middle age have a higher prevalence of type 2 diabetes mellitus compared with women in the same age group [1]. In Sweden, the age-standardized prevalence of pharmacologically and non-pharmacologically treated diabetes was 56% for men and 39% for women in 2012 [2].

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics of repaglinide have been found.


No studies with a clinically relevant sex analysis regarding the effect of repaglinide have been found.

Adverse effects

In a retrospective cohort study from Taiwan including patients with type 2 diabetes treated with glinide (meglitinide/repaglinide) (14 357 men, 11 281 women) a higher risk of hospitalized heart failure was found for women (men: adjusted HR 1.26; 95%CI 0.95-1.68; women: adjusted HR 1.88; 95%CI 1.39-2.55) [3].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2022-11-09

Date of litterature search: 2020-03-03


  1. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia. 2001;44(1):3-15. PubMed
  2. Jansson SP, Fall K, Brus O, Magnuson A, Wändell P, Östgren CJ et al. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. Diabet Med. 2015;32(10):1319-28. PubMed
  3. Lee YC, Chang CH, Dong YH, Lin JW, Wu LC, Hwang JS et al. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study. Int J Cardiol. 2017;228:1007-1014. PubMed
  4. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.] länk

Authors: Emelie Elfving, Linnéa Karlsson Lind

Reviewed by: Carl-Olav Stiller, Diana Rydberg

Approved by: Karin Schenck-Gustafsson